In the past, little or no attention was paid to cognitive disorders associated with depression
(a condition sometimes termed pseudodementia). However, recent years have seen a …

Vortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), is
a 5-HT 3, 5-HT 7 and 5-HT 1D receptor antagonist, 5-HT 1B receptor partial agonist, 5-HT …

Extensive studies showed that monoaminergic neurotransmission that involves serotonin (5-
HT), norepinephrine (NE) and dopamine (DA) exerts major influence on brain circuits …

The efficacy of vortioxetine 10 and 20 mg/d vs. placebo on cognitive function and depression
in adults with recurrent moderate-to-severe major depressive disorder (MDD) was …

This multicenter, randomized, double-blind, placebo-controlled, active-referenced
(duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of …

Antidepressant medications are the first‐line treatment option for moderate to severe major
depressive disorder. However, most antidepressants have numerous documented adverse …

The monoamine hypothesis has been the prevailing hypothesis of depression over the last
several decades. It states that depression is associated with reduced monoamine function …

Increased inflammation in major depressive disorder (MDD) has been associated with low
functional connectivity (FC) in corticostriatal reward circuits and symptoms of anhedonia …

Vortioxetine is a novel antidepressant with multimodal activity currently approved for the
treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5-to …

Neuroimaging studies in humans have demonstrated that inflammatory cytokines target
basal ganglia function and presynaptic dopamine (DA), leading to symptoms of depression …